Photo by bruce mars on Pexels.com

Teva Stock Price Rise as Investors Welcomed Promising Sign of Progress

Technical and Fundamental Analysis of TEVA Stock

By Glenford S. Robinson

Teva pharmaceutical Industries Ltd (NYSE: TEVA) is an Israeli pharmaceutical company developing, producing, and marketing generic medicines including a portfolio of specialty medicines. We will speak about the technical analysis aspect first before we proceed to speaking about the fundamentals. We have derived our technical analysis perspective by using our proprietary trading strategy. So, the technical analysis goes as follows.

Any TEVA stock price falling on or below the hypothesized mean of $22.00, will signal the initiation of a buy order. On the other hand, any price rising above the hypothesized mean of $22.00 or within the range of $22.00 to $23.26 and above, will signal the initiation of a sell order. As of writing this Technical Indicator article, (November 5, 2018) the price of TEVA hit a low of $21.98, which is well within our target range of initiating a buy order.

Therefore, if we had bought the stock at our hypothesized buy range of $22.00 or below, we would have made a nice profit of $0.85 (cents) per share because the stock closed at a $22.85 per share, a change of $0.26 (cents) per share, which is a 1.15% change for the day (November 5, 2018).

Not only that, an early morning trade right after the market opened at 9:45 am would have given us a nice gain of $1.26 per share if we had followed our Mstardom Finance trading strategy of closing our long position or shorting the stock when it got to our range’s upper limit garget of $23.26.

As soon as the price hit our $23.26 target, we would’ve had to exit the trade because in trading, greed causes traders to lose money, so as wise traders, we would’ve exited the trade several minutes before the stock got to its high point of $23.34. The Mstardom Finance community doesn’t care about a few extra pennies when we already got a sizable gain in our basket.

The good thing is that this Mstardom Finance Trading Strategy is still relevant at the present time and in the not-so-distant future, once the hypothesized mean and the character of the TEVA stock stays the same.
We are able to deduce such optimism because the stock has a very low volatility characteristic, based on our analytical assessment lend to us by our proprietary strategy.

All we at Mstardom Finance cares about is helping the retail trader make money. So, when you hop over to Mstardom Finance, you will see articles, posts, and trading tools that provide the little retail trader with resources and information that will help him or her compete with the institutional or professional trader. This is what our upcoming trading book will be about, preventing the retail trader from being victims of the financial markets.

Fundamental Analysis of TEVA Stock

Even though we have thoroughly assessed TEVA using technical analysis, there comes a point where we as responsible influencers in the trading community, must set a good example for up-and-coming retail traders to follow by not only relying on Technical Analysis, but also implementing the very important Fundamental Analysis in our research and assessment of potential stocks to trade. So, here is our take on the Fundamentals of TEVA stock.

Despite some minor setbacks, Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has begun to see promising signs of progress, according to Chief Executive Officer Kare Schultz. The company’s drugs have experienced stiff competition from drug makers that make similar drugs to combat multiple sclerosis.

The company stated that revenue of its generic-drugs business declined 25% to $922 million culminating a series of quarterly decline over the past 7 quarters. Another contributing factor to the company’s struggles is the increase frequency of mergers among pharmacy chains. When pharmacy chains merge or consolidate, this reduces the buying pools of pharmacy outlets available to buy Teva-produced pharmaceutical.

The company’s best-selling multiple sclerosis drug, Copaxone has met stiff competition from rivals that competes with Teva by cutting prices of their drug offerings. Such competition is responsible for a North
American reduction in sales to the tune of 43% to $463 million for the quarter.

However, despite all the negatives that have undermined the company’s progress, there is still positive signs that the company is weathering the storm. This is due to some ambitious measures taken by Mr. Schultz, the company’s top executive. The Chief Executive has implemented some tough cost cutting measures, such as laying off employees (14000) and closing manufacturing facilities, [Dow Jones Newswire, 2018]. In fact, another positive is abound; the company’s recent research drug Celltrion BLA for CT-P10, a proposed Rituximab Biosimilar recently received positive recommendations from the FDA. If FDA approval is granted, CT-P10, a proposed biosimilar to Rituxan ®(rituximab), “will be the first rituximab biosimilar to be approved in the United States” according to the October 10, 2018 FDA Press Release.

As a result of these happenings, investors too have seen evidence of progress and as a result have supported the stock. This positive sentiment of investors has triggered an upward movement of the stock.

The above information was the reason why Teva appeared on the Mstardom Finance Stock Screener Radar. The Mstardom Finance team monitors the financial markets to identify potential winning stocks. After our tool locates a potential winning stock, we then analyze the stock to make sure that its price movement isn’t artificially inflated by looking at confirmatory fundamentals and logical technical analysis.

We then look at historical data of the stock over a predefined period, then placed this data in our proprietary analytical tool. The Mstardom Finance Analytical Tool then gives us all the necessary price points, such as entry points and exit points. For example, the tool tells us when to enter a trade and when to exit that trade.

We then write an article explaining the fundamentals and technical analysis of the stock. Our system also interprets the technical analysis results, so we can write a well- organized and conclusive article about the stock. The steps that we take in developing our trading strategy will be published in our upcoming book.

Sources:

Teva Shares Rise as Investors Greet Progress in Turnaround
9:49 am ET November 1, 2018 (Dow Jones) Print
By Denise Roland

Pharmaceutical Industries Ltd: News Release October 10, 2018 12:30pm

Check Also

GDP Growth Slowed

US Economy Starts to Slow Entering 2019, but Headwinds Ease

The Federal Reserve has signaled that it will postpone further interest rate hikes until signs of rising inflation emerge and cease balance sheet normalization activities towards the end of this year. Stock price gains since the announcement of these policy shifts illustrate that if they are executed, business confidence is likely to rise.

Where can I get business financing?

Horizon Technology Finance Provides Investment Portfolio Update Increases Portfolio Size with $24 Million in Loan Originations; Grows Committed Backlog to $47 Million

"During the third quarter, we experienced solid investment activity, increasing the size of our portfolio and expanding our committed backlog for the second consecutive quarter," said Gerald A. Michaud, President of Horizon. "Our success funding seven loans, totaling more than $24 million, and growing our committed backlog to $47 million underscores the strong demand for our venture debt products to growing life science and technology companies. We believe Horizon will continue to benefit from a robust pipeline of investment opportunities and is well positioned to deliver long-term, disciplined portfolio growth, while ensuring credit quality remains strong."

ECB profit increased in 2018

Financial Statements of the ECB for 2018

The ECB’s net profit is distributed to the euro area national central banks (NCBs). The Governing Council decided to make an interim profit distribution, amounting to €1,191 million, to the euro area NCBs on 31 January 2019. At yesterday’s meeting, the Governing Council decided to distribute the remainder of the profit, amounting to €384 million, on 22 February 2019.

Litigation Photo

Immune Design (IMDZ) Alert: Johnson Fistel Investigates Proposed Sale of Immune Design Corp.; Are Immune Design Shareholders Getting a Fair Deal?

The investigation concerns whether the Immune Design board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Immune Design shares of common stock. Nationally recognized Johnson Fistel is investigating whether the proposed deal represents adequate consideration, especially given that one Wall Street analyst has a $9.00 price target on the stock and the Company has approximately $100 million in cash and no long-term debt.

Mergers and Acquisitions

Merck to Acquire Immune Design; Acquisition Bolsters Capabilities in Vaccine Development for Infectious Diseases and Cancer

“Scientists at Immune Design have established a unique portfolio of approaches to cancer immunization and adjuvant systems designed to enhance the ability of a vaccine to protect against infection, which could meaningfully improve vaccine development," said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. “This acquisition builds upon Merck’s industry-leading programs that harness the power of the immune system to prevent and treat disease.”

SEC Files Charges in Elaborate Microcap Stock Fraud

“As alleged in our complaint, Magna Group and its co-defendants used fake debt instruments to unlawfully obtain shares in microcap companies, which they then dumped on unsuspecting retail investors,” said Sanjay Wadhwa, Senior Associate Director of the SEC’s New York Regional Office. “This action demonstrates the resolve of the SEC in pursuing fraudsters who use elaborate financing schemes to engage in securities fraud.”

Investor Alert and Bulletin From SEC Office of Investor Education and Advocacy

Know how to be a better investor. Did you know that active trading and some other very common investing behaviors actually can undermine investment performance? According to researchers, other common investing mistakes include focusing on past performance, favoring investments from your own country, region, state, or company, and holding on to losing investments too long and selling winning investments too soon.

%d bloggers like this: